- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT05803382
Тестирование добавления противоракового препарата ZEN003694 к обычному химиотерапевтическому лечению (капецитабин) метастатического или нерезектабельного рака
Испытание фазы I ZEN003694 (ZEN-3694) в комбинации с капецитабином у пациентов с солидными опухолями
This phase I trial tests the safety, side effects, and best dose of ZEN003694 in combination with the usual treatment with capecitabine in treating patients with cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable) and that it has progressed on previous standard treatment. ZEN003694 is an inhibitor of a family of proteins called the bromodomain and extra-terminal (BET). It may prevent the growth of tumor cells that over produce BET protein. Capecitabine is in a class of medications called antimetabolites. It is taken up by cancer cells and breaks down into fluorouracil, a substance that kills cancer cells. Giving ZEN003694 in combination with capecitabine may be safe in treating patients with metastatic or unresectable solid tumors.
Обзор исследования
Статус
Условия
Подробное описание
PRIMARY OBJECTIVE:
I. To determine the safety and tolerability, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of BET bromodomain inhibitor ZEN-3694 (ZEN003694 [ZEN-3694]) in combination with capecitabine in patients with solid tumors.
SECONDARY OBJECTIVES:
I. To observe and record anti-tumor activity of ZEN003694 (ZEN-3694) in combination with capecitabine.
II. To determine the pharmacokinetics (PK) of ZEN003694 (ZEN-3694) in combination with capecitabine.
III. To determine the pharmacodynamics (PD) of ZEN003694 (ZEN-3694) in combination with capecitabine (death receptor 5 [DR5] dynamics and apoptosis).
IV. To identify molecular subpopulations particularly sensitized to bromodomain and extra-terminal motif inhibitor (BETi) and capecitabine.
OUTLINE: This is a dose-escalation study of ZEN003694 and capecitabine, followed by a dose-expansion study.
Patients receive ZEN003694 orally (PO) once daily (QD) and capecitabine PO twice daily (BID) 2 weeks on, 1 week off during each treatment cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. NOTE: Patients do not receive ZEN003694 on day 1 of cycle 1. Patients undergo computed tomography (CT) or magnetic resonance imaging (MRI), positron emission tomography (PET)/CT, and collection of blood samples throughout the trial. Patients may also undergo biopsies during screening and while on the study.
After completion of study treatment, patients are followed up for safety 30 days after the last dose, and then every 3 months for 12 months.
Тип исследования
Регистрация (Оцененный)
Фаза
- Фаза 1
Контакты и местонахождение
Места учебы
-
-
California
-
Irvine, California, Соединенные Штаты, 92612
- Рекрутинг
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
-
Контакт:
- Site Public Contact
- Номер телефона: 877-827-8839
- Электронная почта: ucstudy@uci.edu
-
Главный следователь:
- Fa-Chyi Lee
-
Orange, California, Соединенные Штаты, 92868
- Рекрутинг
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Контакт:
- Site Public Contact
- Номер телефона: 877-827-8839
- Электронная почта: ucstudy@uci.edu
-
Главный следователь:
- Fa-Chyi Lee
-
-
Florida
-
Gainesville, Florida, Соединенные Штаты, 32610
- Рекрутинг
- UF Health Cancer Institute - Gainesville
-
Контакт:
- Site Public Contact
- Номер телефона: 352-273-8010
- Электронная почта: cancer-center@ufl.edu
-
Главный следователь:
- Thomas J. George
-
-
Illinois
-
Shiloh, Illinois, Соединенные Штаты, 62269
- Активный, не рекрутирующий
- Memorial Hospital East
-
-
Kansas
-
Fairway, Kansas, Соединенные Штаты, 66205
- Рекрутинг
- University of Kansas Clinical Research Center
-
Контакт:
- Site Public Contact
- Номер телефона: 913-588-3671
- Электронная почта: KUCC_Navigation@kumc.edu
-
Главный следователь:
- Joaquina C. Baranda
-
Kansas City, Kansas, Соединенные Штаты, 66160
- Рекрутинг
- University of Kansas Cancer Center
-
Контакт:
- Site Public Contact
- Номер телефона: 913-588-3671
- Электронная почта: KUCC_Navigation@kumc.edu
-
Главный следователь:
- Joaquina C. Baranda
-
Westwood, Kansas, Соединенные Штаты, 66205
- Рекрутинг
- University of Kansas Hospital-Westwood Cancer Center
-
Контакт:
- Site Public Contact
- Номер телефона: 913-588-3671
- Электронная почта: KUCC_Navigation@kumc.edu
-
Главный следователь:
- Joaquina C. Baranda
-
-
Missouri
-
City of Saint Peters, Missouri, Соединенные Штаты, 63376
- Активный, не рекрутирующий
- Siteman Cancer Center at Saint Peters Hospital
-
Creve Coeur, Missouri, Соединенные Штаты, 63141
- Активный, не рекрутирующий
- Siteman Cancer Center at West County Hospital
-
St Louis, Missouri, Соединенные Штаты, 63110
- Активный, не рекрутирующий
- Washington University School of Medicine
-
St Louis, Missouri, Соединенные Штаты, 63129
- Активный, не рекрутирующий
- Siteman Cancer Center-South County
-
St Louis, Missouri, Соединенные Штаты, 63136
- Активный, не рекрутирующий
- Siteman Cancer Center at Christian Hospital
-
-
New York
-
New York, New York, Соединенные Штаты, 10032
- Рекрутинг
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
Главный следователь:
- Ryan Moy
-
Контакт:
- Site Public Contact
- Номер телефона: 212-342-5162
- Электронная почта: cancerclinicaltrials@cumc.columbia.edu
-
The Bronx, New York, Соединенные Штаты, 10461
- Рекрутинг
- Montefiore Medical Center-Einstein Campus
-
Контакт:
- Site Public Contact
- Номер телефона: 718-379-6866
- Электронная почта: eskwak@montefiore.org
-
Главный следователь:
- Chaoyuan Kuang
-
The Bronx, New York, Соединенные Штаты, 10467
- Рекрутинг
- Montefiore Medical Center - Moses Campus
-
Контакт:
- Site Public Contact
- Номер телефона: 718-379-6866
- Электронная почта: eskwak@montefiore.org
-
Главный следователь:
- Chaoyuan Kuang
-
The Bronx, New York, Соединенные Штаты, 10461
- Рекрутинг
- Montefiore Medical Center-Weiler Hospital
-
Контакт:
- Site Public Contact
- Номер телефона: 718-379-6866
- Электронная почта: eskwak@montefiore.org
-
Главный следователь:
- Chaoyuan Kuang
-
-
Ohio
-
Cincinnati, Ohio, Соединенные Штаты, 45219
- Рекрутинг
- University of Cincinnati Cancer Center-UC Medical Center
-
Контакт:
- Site Public Contact
- Номер телефона: 513-584-7698
- Электронная почта: cancer@uchealth.com
-
Главный следователь:
- Davendra P. Sohal
-
West Chester, Ohio, Соединенные Штаты, 45069
- Рекрутинг
- University of Cincinnati Cancer Center-West Chester
-
Контакт:
- Site Public Contact
- Номер телефона: 513-584-7698
- Электронная почта: cancer@uchealth.com
-
Главный следователь:
- Davendra P. Sohal
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Соединенные Штаты, 73104
- Рекрутинг
- University of Oklahoma Health Sciences Center
-
Контакт:
- Site Public Contact
- Номер телефона: 405-271-8777
- Электронная почта: ou-clinical-trials@ouhsc.edu
-
Главный следователь:
- Susanna V. Ulahannan
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Соединенные Штаты, 15232
- Рекрутинг
- UPMC Hillman Cancer Center
-
Контакт:
- Site Public Contact
- Номер телефона: 412-647-8073
-
Главный следователь:
- Anwaar Saeed
-
-
Tennessee
-
Nashville, Tennessee, Соединенные Штаты, 37232
- Рекрутинг
- Vanderbilt University/Ingram Cancer Center
-
Контакт:
- Site Public Contact
- Номер телефона: 800-811-8480
-
Главный следователь:
- Thatcher R. Heumann
-
Nashville, Tennessee, Соединенные Штаты, 37204
- Рекрутинг
- Vanderbilt Breast Center at One Hundred Oaks
-
Контакт:
- Site Public Contact
- Номер телефона: 800-811-8480
-
Главный следователь:
- Thatcher R. Heumann
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Dose Escalation additional criteria: Patients must have histologically confirmed cancer that is metastatic or unresectable and must have progressed on standard therapies which would have included fluorouracil (5-FU) or capecitabine
- Dose Escalation additional criteria specifically for colorectal cancer (CRC) patients: Willingness and ability to undergo a pre-treatment biopsy
- Dose Expansion additional criteria: Patients must have histologically confirmed CRC that is metastatic or unresectable and must have progressed on standard therapies which would have included 5-FU or capecitabine
- Dose Expansion additional criteria: Willingness and ability to undergo pre- and on- treatment biopsies
- Patients must have measurable disease
- Age >= 18 years. Because no dosing or adverse event data are currently available on the use of ZEN003694 (ZEN-3694) in combination with capecitabine in patients < 18 years of age, children are excluded from this study
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 (Karnofsky >= 60%)
- Availability of archival tumor tissue at the time of patient enrollment for molecular profiling studies
- Prior to study dosing, previous systemic therapy must have been completed for at least five half-lives or 2 weeks, whichever is shorter
- Absolute neutrophil count >= 1,000/mcL
- Platelets >= 100,000/mcL
- Total bilirubin =< 1.5 institutional upper limit of normal (ULN)
- Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional ULN
- Glomerular filtration rate (GFR) >= 50 mL/min/1.73 m^2
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
- Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression
- Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
- Patients should be New York Heart Association Functional Classification of class 2B or better
- The effects of ZEN003694 (ZEN-3694) and capecitabine on the developing human fetus are unknown. For this reason and because BET inhibitors as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Women of child-bearing potential and men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of ZEN003694 (ZEN-3694) and capecitabine administration
- Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants
Exclusion Criteria:
- Previous treatment with BET inhibitors
- History of inability to tolerate capecitabine at the projected treatment dose on this trial
- Use of oral Factor Xa inhibitors (i.e., rivaroxaban, apixaban, betrixaban, edoxaban otamixaban, letaxaban, eribaxaban) and Factor IIa inhibitors (i.e., dabigatran). Low molecular weight heparin is allowed
- Treatment for HIV, hepatitis B or hepatitis C only if this interferes with the current treatment (e.g. through drug-drug interactions)
- Gastrointestinal pathology or history that adversely impacts the ability to take or absorb oral medication
- Hepatic tumor burden > 30% or peritoneal carcinomatosis
- Untreated/uncontrolled central nervous system (CNS) disease
- Known dihydropyrimidine dehydrogenase (DPD) deficiency
- Severe intercurrent illness or comorbidity
- Inability to comply with the protocol and/or not willing or who will not be available for follow-up assessments
- Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia and neuropathy up to and including grade 2
- Patients who are receiving any other investigational agents
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to ZEN003694 (ZEN-3694) or other agents used in study
- Patients receiving any medications or substances that are strong inhibitors or inducers of CYP3A4 are ineligible. Strong inhibitors of CYP3A4 must be discontinued at least 7 days, and inducers 14 days prior to the first dose of ZEN003694 and capecitabine. Substrates of CYP1A2 with narrow therapeutic window must be avoided while taking ZEN003694
- Pregnant women are excluded from this study because ZEN003694 (ZEN-3694) is an agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ZEN003694 (ZEN-3694), breastfeeding should be discontinued if the mother is treated with ZEN003694 (ZEN-3694). These potential risks may also apply to other agents used in this study
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Н/Д
- Интервенционная модель: Одногрупповое задание
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Treatment (ZEN003694, capecitabine)
Patients receive ZEN003694 PO QD and capecitabine PO BID 2 weeks on, 1 week off during each treatment cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. NOTE: Patients do not receive ZEN003694 on day 1 of cycle 1. Patients undergo CT or MRI, PET/CT, and collection of blood samples throughout the trial. Patients may also undergo biopsies during screening and while on the study. |
Undergo MRI
Другие имена:
Undergo biopsy
Другие имена:
Undergo collection of blood samples
Другие имена:
Undergo PET/CT
Другие имена:
Given PO
Другие имена:
Given PO
Другие имена:
Undergo CT and PET/CT
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Incidence of adverse events
Временное ограничение: Up to 30 days after last dose
|
Adverse events and serious adverse events will be tabulated for each dose levels. As per National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0, the term toxicity is defined as adverse events that are classified as either possibly, probably, or definitely related to study treatment. The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns. |
Up to 30 days after last dose
|
|
Maximum tolerated dose (MTD)
Временное ограничение: During the first cycle of therapy (Cycles = 21 days)
|
Defined as the highest dose level with no more than 1/6 dose-limiting toxicity. Dose level 4 was selected as the MTD. |
During the first cycle of therapy (Cycles = 21 days)
|
|
Recommended phase 2 dose (RP2D)
Временное ограничение: Up to 30 days after last dose
|
Dose level 4 was selected as the RP2D. |
Up to 30 days after last dose
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Anti-tumor activity of ZEN003694 (ZEN-3694) in combination with capecitabine
Временное ограничение: Up to 12 months
|
Treatment response will be assessed for all patients based on Response Evaluation Criteria in Solid Tumors version 1.1: complete response (CR), partial response (PR), stable disease (SD), and progression of disease (PD). Clinical benefit rate is defined as the addition of CR, PR and SD. |
Up to 12 months
|
|
Progression free survival (PFS)
Временное ограничение: Up to 12 months
|
PFS will be estimated by the Kaplan-Meier method, along with 95% confidence regions. |
Up to 12 months
|
|
Objective response rate (ORR)
Временное ограничение: Up to 12 months
|
Defined as the addition of CR and PR. The probability of ORR and clinical benefit rate will be estimated with exact 95% binomial confidence intervals. |
Up to 12 months
|
|
Pharmacokinetics (PK) of ZEN003694 (ZEN-3694) in combination with capecitabine
Временное ограничение: Up to 12 months
|
Will determine the PK of ZEN003694 (ZEN-3694) in combination with capecitabine. Capecitabine PK will be evaluated in the absence and presence of ZEN003694 (ZEN-3694) and Cmax and area under curve (AUC) will be compared with a paired test. ZEN003694 (ZEN-3694) PK will be evaluated in the presence of capecitabine and Cmax and AUC will be compared descriptively with historical data. |
Up to 12 months
|
|
Pharmacodynamics (PD) of ZEN003694 (ZEN-3694) in combination with capecitabine
Временное ограничение: Up to 12 months
|
Will determine PD of ZEN003694 (ZEN-3694) in combination with capecitabine. Ribonucleic acid sequencing of death receptor 5 (DR5). DR5 is expected to be increased by the combination ZEN003694 (ZEN-3694) in combination with capecitabine. Pre-post comparisons will be made within patients enrolled on the expansion cohort using a non-parametric paired test, at a significance level (alpha) of 0.05. Apoptosis by Pharmacodynamic Assay Development and Implementation Section (PADIS) lab. Panel 3 is priority, but other panels will be evaluated with remaining lysate. Apoptosis is expected to be increased by the combination ZEN003694 (ZEN-3694) in combination with capecitabine. Pre-post comparisons will be made within patients enrolled on the expansion cohort using a non-parametric paired test, at a significance level (alpha) of 0.05. |
Up to 12 months
|
|
Molecular subpopulations particularly sensitized to BETi and capecitabine
Временное ограничение: Up to 12 months
|
Will identify molecular subpopulations particularly sensitized to BETi and capecitabine. Based on WES of archival tissue, we will evaluate descriptively any mutations in genes relevant to DNA damage repair, signaling and (fluoropyrimidine) metabolism, any relations with peculiar response and/or toxicity. |
Up to 12 months
|
Соавторы и исследователи
Спонсор
Следователи
- Главный следователь: Anwaar Saeed, University of Pittsburgh Cancer Institute LAO
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
- Патологические процессы
- Новообразования по локализации
- Новообразования
- Кишечные заболевания
- Желудочно-кишечные новообразования
- Новообразования пищеварительной системы
- Заболевания пищеварительной системы
- Желудочно-кишечные заболевания
- Новообразования кишечника
- Заболевания прямой кишки
- Заболевания толстой кишки
- Неопластические процессы
- Патологические состояния, признаки и симптомы
- Колоректальные новообразования
- Метастаз новообразования
- Гетероциклические соединения, 1-кольцо
- Гетероциклические соединения
- Следственные методы
- Клинические лабораторные методы
- Диагностические методы и процедуры
- Диагноз
- Хирургические процедуры, оперативные
- Цитологические методы
- Нуклеиновые кислоты, нуклеотиды и нуклеозиды
- Цитодиагностика
- Дезоксицитидин
- Цитидин
- Пиримидиновые нуклеозиды
- Пиримидины
- Диагностические методы, хирургический
- Химические методы, аналитические
- Анализ спектра
- Нуклеозиды
- Урацил
- Пиримидиноны
- Дезоксирибонуклеозиды
- Флуорурацил
- Капецитабин
- Биопсия
- Обработка образца
- Магнитно -резонансная спектроскопия
Другие идентификационные номера исследования
- NCI-2023-02652
- UM1CA186690 (Грант/контракт NIH США)
- 10579 (Другой идентификатор: CTEP)
- NCI-2023-02652 (Идентификатор реестра: CTRP (Clinical Trial Reporting Program))
- HCC 23-096
- 10579 (Другой идентификатор: UPMC Hillman Cancer Center LAO)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
"NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page."
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
продукт, произведенный в США и экспортированный из США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .